Rankings
▼
Calendar
URGN Q4 2018 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$918M
Q4 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$24M
Net Income
-$24M
EPS (Diluted)
$-1.46
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$104M
Total Liabilities
$13M
Stockholders' Equity
$90M
Cash & Equivalents
$101M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$327,000
-100.0%
Gross Profit
$0
$40,000
-100.0%
Operating Income
-$24M
-$10M
-136.4%
Net Income
-$24M
-$10M
-135.6%
← FY 2018
All Quarters
Q1 2019 →